Nonfactor Therapies for Hemophilia
Hemophilia is a congenital, X-linked bleeding disorder caused by deficiencies in coagulation factor VIII (FVIII) or factor IX (FIX) due to mutations in the F8 or F9 genes on the X chromosome.
These deficiencies impair thrombin generation, resulting in a lifelong predisposition to bleeding. Hemophilia A is more common, with a prevalence of approximately 1 in 4,000 male live births, compared to 1 in 20,000 male live births for hemophilia B.
Female carriers are about 1.6 times more prevalent than affected males, with some carriers experiencing reduced factor levels and clinically significant bleeding.
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
Author's summary: Hemophilia is a genetic bleeding disorder with two main types, A and B.
More News
- MEG takeover vote postponed again over questions about Cenovus-Strathcona side deal
- 'Hotel Transylvania' spinoff 'Motel Transylvania' delayed, now set for 2027 release on Netflix | The Express Tribune
- How Samsung And NVIDIA Are Partnering To Build A Megafactory - TechRound
- East Georgia Regional Medical Center celebrates family at 5th annual Halloween Fest
- Cineworld announces luxury upgrade at Silverburn with new recliner seats
- Meta’s Chatbot Data Grab Sparks Privacy Alarm
- When skeletons come out of the closet and onto the street - Washington Square News
- Ayuba Sylvester James: “For MCP to Rise, Chakwera Must Fall” - Malawi Nyasa Times - News from Malawi about Malawi
- Wordle Hints Today: Answer for October 31, 2025
- REALM GlobalLuxury Real Estate Membership Platform Unveils New White Paper On AI Adoption in Luxury Real Estate